首页> 外文OA文献 >P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers

【2h】

P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers

机译：P369在健康志愿者中的剂量升级后，口服，有效，下一代选择性S1P受体调节剂，口服，有效，下一代选择性S1P受体调节剂的安全性和淋巴细胞降低性能

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
L. Peyrin-Biroulet; R. Christopher; L. Trokan; C. Lassen; J. Adams; T. Kühbacher;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A Randomized, Double-Blind, Placebo-Controlled Trial of a Selective, Oral Sphingosine 1-Phosphate (S1P) Receptor Modulator, Etrasimod (APD334), in Moderate to Severe Ulcerative Colitis (UC): Results From the OASIS Study [J] . Sandborn William J., Peyrin-Biroulet Laurent, Trokan Luba, The American Journal of Gastroenterology . 2018,第Suppla2期

机译：选择性口服鞘氨酸1-磷酸（S1P）受体调节剂，eTraasimod（APD334），中度至重度溃疡性结肠炎（UC）的随机，双盲，安慰剂对照试验：来自OASIS研究的结果
2. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid-1 Receptor Inverse Agonist, for the Treatment of Obesity : Results From a Double-Blind, Placebo-Controlled, Single Oral Dose Study in Healthy Volunteers [J] . Addy C, Li S, Agrawal N, The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology . 2008,第4期

机译：新型选择性大麻素1受体逆激动剂Taranabant的安全性，耐受性，药代动力学和药代动力学特性，用于治疗肥胖症：健康志愿者的双盲，安慰剂对照，单次口服剂量研究的结果
3. Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of ASP2408, a Potent Selective T-Cell Costimulation Modulator After Single and Multiple Ascending Doses in Healthy Volunteers and RA Patients [J] . Tong Zhu, James Keirns, Corrie Howieson, Clinical pharmacology in drug development . 2016,第5期

机译：ASP2408的药代动力学，药效动物，安全性和耐受性，在健康志愿者和RA患者中单一和多种上升剂量后的有效的选择性T细胞共抑制调节剂
4. A Phase I, Double-Blind, Randomized, Dose Escalating Crossover Study ofan Oral Formulation of Human Growth Hormone in Healthy Male Volunteers [C] . Steven M. Dinh, Puchun Liu, Ehud Arbit, Controlled Release Society annual meeting . 2004

机译：健康男性志愿者中人类生长激素口服制剂的I期，双盲，随机，剂量递增交叉研究
5. Dose Escalation Study of the Safety Tolerability and Pharmacokinetics of Nemonoxacin (TG-873870) a Novel Potent Broad-Spectrum Nonfluorinated Quinolone in Healthy Volunteers [O] . Luke Lin, Li-Wen Chang, Cheng-Yuan Tsai, 2010

机译：新型有效的广谱非氟化喹诺酮药物Nemonoxacin（TG-873870）的安全性耐受性和药代动力学在健康志愿者中的剂量递增研究
6. DOP078 Pharmacology and safety of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator [O] . T. Kühbacher, R. Christopher, L. Trokan, 2017

机译：DOP078 ETRASIMOD的药理学和安全性（APD334），口服，有效，下一代选择性S1P受体调节剂

P369 Safety and lymphocyte-lowering properties of etrasimod (APD334), an oral, potent, next-generation, selective S1P receptor modulator, after dose escalation in healthy volunteers

著录项

引文网络

相似文献

相关主题

期刊订阅